Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wildtype metastatic colorectal cancer patients

被引：1
作者：
Cristiana Lo Nigro [1 ]
Vincenzo Ricci [2 ]
Daniela Vivenza [1 ]
Martino Monteverde [1 ]
Giuliana Strola [3 ]
Francesco Lucio [4 ]
Federica Tonissi [1 ]
Emanuela Miraglio [2 ]
Cristina Granetto [2 ]
Mirella Fortunato [5 ]
Marco Carlo Merlano [2 ]
机构：
[1] Laboratory of Cancer Genetics and Translational Oncology,Oncology Department,S.Croce and Carle Teaching Hospital
[2] Medical Oncology,Oncology Department,S.Croce and Carle Teaching Hospital
[3] Laboratory Department,S.Croce and Carle Teaching Hospital
[4] Radiotherapy Department,S.Croce and Carle Teaching Hospital
[5] Pathology Department,S.Croce and Carle Teaching Hospital
来源：
World Journal of Gastrointestinal Oncology | 2016年 / 02期
关键词：
Metastatic colorectal cancer; Single nucleotide polymorphism in Fc-γ receptors; Cetuximab; RAS family; Antibody-dependent cell-mediated cytotoxicity; Invariant natural killer T cells;
D O I：
暂无
中图分类号：
R735.34 [];
学科分类号：
100214 ;
摘要：
AIM:To investigate the prognostic role of invariant natural killer T(iNKT) cells and antibody-dependent cell-mediated cytotoxicity(ADCC) in wild type KRAS metastatic colorectal cancer(mC RC) patients treated with cetuximab.METHODS: Forty-one KRAS wt mC RC patients,treated with cetuximab and irinotecan-based chemotherapy in Ⅱ and Ⅲ lines were analyzed. Genotyping of single nucleotide polymorphism(SNP)s in the FCGR2A,FCGR3A and in the 3’ untranslated regions of KRAS and mutational analysis for KRAS,BRAF and NRAS genes was determined either by sequencing or allelic discrimination assays. Enriched NK cells were obtained from lymphoprepperipheral blood mononuclear cell and iN KT cells were defined by co-expression of CD3,TCRVα24,TCRVβ11. ADCC was evaluated as ex vivo NK-dependent activity,measuring lactate dehydrogenase release.RESULTS: At basal,mCRC patients performing ADCC activity above the median level(71%) showed an improved overall survival(OS) compared to patients with ADCC below(median 16 vs 8 mo;P=0.026). We did not find any significant correlation of iN KT cells with OS(P=0.19),albeit we observed a trend to a longer survival after 10 mo in patients with iN KT above median basal level(0.382 cells/microliter). Correlation of OS and progression-free survival(PFS) with interesting SNPs involved in ADCC ability revealed not to be significant. Patients carrying alleles both with A in FCGR2 A and TT in FCGR3A presented a trend of longer PFS(median 9 vs 5 mo;P=0.064). Chemotherapy impacted both iN KT cells and ADCC activity. Their prognostic values get lost when we analysed them after 2 and 4 mo of treatment.CONCLUSION: Our results suggest a link between iN KT cells,basal ADCC activity,genotypes in FCGR2A and FCGR3A,and efficacy of cetuximab in KRAS wt mC RC patients.
引用
收藏
页码：222 / 230
页数：9
相关论文
共 10 条
[1]  
The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients[J] . Martino Monteverde,Gerard Milano,Giuliana Strola,Monica Maffi,Laura Lattanzio,Daniela Vivenza,Federica Tonissi,Marco Merlano,Cristiana Lo Nigro. Critical Reviews in Oncology / Hematology . 2015 (2)
[2]   Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer [J].
Seo, Yuki ;
Ishii, Yoshiyuki ;
Ochiai, Hiroki ;
Fukuda, Kazumasa ;
Akimoto, Shingo ;
Hayashida, Tetsu ;
Okabayashi, Koji ;
Tsuruta, Masashi ;
Hasegawa, Hirotoshi ;
Kitagawa, Yuko .
ONCOLOGY REPORTS, 2014, 31 (05) :2115-2122
[3]   KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells [J].
Nakadate, Yusuke ;
Kodera, Yasuo ;
Kitamura, Yuka ;
Shirasawa, Senji ;
Tachibana, Taro ;
Tamura, Tomohide ;
Koizumi, Fumiaki .
INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (09) :2146-2155
[4]   Combination strategies to enhance antitumor ADCC [J].
Kohrt, Holbrook E. ;
Houot, Roch ;
Marabelle, Aurelien ;
Cho, Hearn Jay ;
Osman, Keren ;
Goldstein, Matthew ;
Levy, Ronald ;
Brody, Joshua .
IMMUNOTHERAPY, 2012, 4 (05) :511-527
[5]  
Natural Killer Cells in Human Cancer: From Biological Functions to Clinical Applications[J] . Estrella Mariel Levy,María Paula Roberti,José Mordoh,Roberto Biassoni. Journal of Biomedicine and Biotechnology . 2011
[6]  
Effects of KRAS, BRAF, NRAS , and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis[J] . Wendy De Roock,Bart Claes,David Bernasconi,Jef De Schutter,Bart Biesmans,George Fountzilas,Konstantine T Kalogeras,Vassiliki Kotoula,Demetris Papamichael,Pierre Laurent-Puig,Frédérique Penault-Llorca,Philippe Rougier,Bruno Vincenzi,Daniele Santini,Giuseppe Tonini,Federico Cappuzzo,Milo Frattini,Fr
[7]   Oncogenic KRAS Desensitizes Colorectal Tumor Cells to Epidermal Growth Factor Receptor Inhibition and Activation [J].
van Houdt, Winan J. ;
Hoogwater, Frederik J. H. ;
de Bruijn, Menno T. ;
Emmink, Benjamin L. ;
Nijkamp, Maarten W. ;
Raats, Danielle A. E. ;
van der Groep, Petra ;
van Diest, Paul ;
Rinkes, Inne H. M. Borel ;
Kranenburg, Onno .
NEOPLASIA, 2010, 12 (06) :443-U23
[8]   FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck [J].
Taylor, Rodney J. ;
Chan, Siaw-Lin ;
Wood, Aaron ;
Voskens, Caroline J. ;
Wolf, Jeffrey S. ;
Lin, Wei ;
Chapoval, Andrei ;
Schulze, Dan H. ;
Tian, Guoliang ;
Strome, Scott E. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (07) :997-1006
[9]   Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies [J].
Iannello, A ;
Ahmad, A .
CANCER AND METASTASIS REVIEWS, 2005, 24 (04) :487-499
[10]  
Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population[J] . Kazue Imai,Satoru Matsuyama,Satoshi Miyake,Kenji Suga,Kei Nakachi. The Lancet . 2000 (9244)
1